Finance

Beta
Lists
TMO:NYSE
Thermo Fisher Scientific Inc
$513.03
+1.43%
(+7.22) 1D
$512.00
-0.20% (-1.03)
After hours
Closed: Jun 26, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMO...
Open
$509.73
High
$514.80
Low
$499.56
Mkt. cap
190.65B
Avg. vol.
2.38M
Volume
4.57M
Dividend
0.37%
Quarterly dividend
$0.47
Ex-dividend date
Jun 15, 2026
P/E ratio
28.23
52-wk high
$643.99
52-wk low
$401.45
EPS
$18.17
Beta
0.88
Shares outstanding
371.62M
No. of employees
125K
Open
$509.73
High
$514.80
Low
$499.56
Mkt. cap
190.65B
Avg. vol.
2.38M
Volume
4.57M
Dividend
0.37%
Quarterly dividend
$0.47
Ex-dividend date
Jun 15, 2026
P/E ratio
28.23
52-wk high
$643.99
52-wk low
$401.45
EPS
$18.17
Beta
0.88
Shares outstanding
371.62M
No. of employees
125K
News stories
From sources across the web
Profile
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD. It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion. Wikipedia
About Thermo Fisher Scientific Inc
CEOMarc N. Casper
Employees125K
Founded1956
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websitethermofisher.com
Analyst ratings
Based on 21 analysts giving stock ratings to TMO in the past 3 months
Strong buy
Buy
16
Hold
5
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for TMO in the last 3 months.
Highest
Current $513.03
$685.00 (+33.52%)
Average
$590.78 (+15.16%)
Lowest
$490.00 (-4.49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eve Burstein
Bernstein
Hold
Reiterated
$520.00
+1.4%
06/25/2026
Luke Sergott
Barclays
Buy
Maintained
$625.00
+21.8%
06/24/2026
Matt Larew
William Blair
Buy
Reiterated
-
-
06/12/2026
David Westenberg
Piper Sandler
Hold
Initiated
$510.00
-0.6%
06/11/2026
Sidharth Sahoo
HSBC
Hold
Downgraded
$540.00
+5.3%
06/03/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
$630.00
+22.8%
06/02/2026
Michael Polark
Wolfe Research
Buy
Initiated
$535.00
+4.3%
06/01/2026
Tycho Peterson
Jefferies
Buy
Maintained
$650.00
+26.7%
05/27/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$600.00
+17%
05/21/2026
Unknown Analyst
Jefferies
Buy
Maintained
$585.00
+14%
05/21/2026
Brandon Couillard
Wells Fargo
Buy
Reiterated
$615.00
+19.9%
05/21/2026
Daniel Brennan
TD Cowen
Buy
Maintained
-
-
05/20/2026
Dan Leonard
RBC Capital
Hold
Initiated
$490.00
-4.5%
05/14/2026
Unknown Analyst
RBC Capital
Hold
Initiated
$490.00
-4.5%
05/14/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Bill Selesky
Argus Research
Buy
Maintained
$560.00
+9.2%
04/30/2026
Unknown Analyst
Argus Research
Buy
Maintained
$560.00
+9.2%
04/30/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$620.00
+20.9%
04/27/2026
Jill Wu
CMB International Securities
Buy
Maintained
$620.00
+20.9%
04/27/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$600.00
+17%
04/24/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$639.00
+24.6%
04/24/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Maintained
$620.00
+20.9%
04/17/2026
Patrick B Donnelly
Citi
Buy
Maintained
$685.00
+33.5%
04/06/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$575.00
+12.1%
04/06/2026
Last report
Apr 23, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$5.44 / $5.24
+3.79%beat
Revenue / Est. (USD)
11.00B / 10.86B
+1.33%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.86B
11.12B
12.22B
11.00B
Cost of goods sold
6.44B
6.53B
7.17B
6.56B
Cost of revenue
6.44B
6.53B
7.17B
6.56B
Research and development expenses
352.00M
346.00M
356.00M
336.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.12B
2.10B
2.24B
2.14B
Operating expense
2.48B
2.45B
2.46B
2.48B
Total operating expenses
8.92B
8.98B
9.63B
9.04B
Operating income
1.94B
2.14B
2.59B
1.97B
Other non operating income
-14.00M
-32.00M
-32.00M
-15.00M
EBT including unusual items
1.71B
1.83B
2.12B
1.73B
EBT excluding unusual items
1.82B
2.03B
2.44B
1.83B
Income tax expense
92.00M
207.00M
153.00M
70.00M
Effective tax rate
5.38%
11.32%
7.21%
4.06%
Other operating expenses
-
-
-135.00M
1.00M
Net income
1.62B
1.62B
1.96B
1.65B
Net profit margin
14.90%
14.53%
16.08%
15.00%
Earnings per share
5.36
5.79
6.57
5.44
Interest and investment income
297.00M
234.00M
258.00M
233.00M
Interest expense
-404.00M
-347.00M
-365.00M
-354.00M
Net interest expenses
-107.00M
-113.00M
-107.00M
-121.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.61B
2.82B
3.31B
2.70B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of TMO
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer